ARCHIVES

Afinitor Increases Overall Survival To 3.5 Years in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

In Brief: Wyngaarden To Leave This summer; Fauci Probably Could Have The Job, May No Want It

April 28, 1989

In Brief: Indiana U. Planning “World Class” Cancer Center; UCLA Names Two New Cancer Control Directors

June 6, 1986

In Brief: O’Conor Now Top Prospect If Rauscher Leaves; Flood Gives NCI Increase Of Only $11 Million

May 14, 1976

CMS to delay final rule publication for oncology.

October 31, 2003

NIH Revises Application Receipt Dates

November 22, 1985

Cancer Groups Propose Six Characteristics Of Next FDA Head.

December 19, 2008